Evaluate is predicting Novo's Cagrisema could rake in more than $17.2 billion in annual sales by 2032.
The hosts break down Fierce Pharma's annual report on the most anticipated drug launches of 2026, led by next-generation obesity medications from Novo Nordisk and Eli Lilly projected to generate tens of billions in sales. They compare the list to previous years, analyze the regulatory timelines, and explore the broader portfolio of candidates across cancer, neurology, and inflammatory diseases.
